PricewaterhouseCoopers

Bellerophon Therapeutics names Jonathan Peacock chairman and CEO

Wednesday, July 2, 2014 11:37 AM

Bellerophon Therapeutics, a clinical stage biotherapeutics company, has announced that Jonathan Peacock has been appointed chairman and CEO. Peacock assumes the role from Daniel Tasse, chairman and CEO of Ikaria, who was interim chairman and CEO of Bellerophon since the company's spin-out from Ikaria in February. Tasse will continue as a member of the board of Bellerophon.

More... »

WIRB Copernicus Group

Report: Value of U.S. health services M&A deals up 152%

Wednesday, May 21, 2014 01:29 PM

U.S. health services M&A total deal value rose 152% to $12.3 billion during the first quarter of 2014 compared to the same period in 2013, according to an analysis of M&A trends and outlook for the health services sector issued by PricewaterhouseCoopers U.S.

More... »

CRF Health eCOA webinar series

Report: Total VC investment in Q1 2014 highest since 2001

Monday, April 21, 2014 02:34 PM

Venture capitalists invested $9.5 billion in 951 deals in the first quarter of 2014, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters

More... »

Report: Venture capital in life sciences sector trailing other industries

Wednesday, February 19, 2014 01:14 PM

Venture capital funding for the life sciences sector, which includes biotechnology and medical devices, declined in 2013 by 1% in dollars invested and 3% in number of deals, compared to 2012, according to a new PwC U.S. report, Medtech Slowdown, which includes data from the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters

More... »

Report: Strong Q4 M&A momentum expected to continue into 2014

Wednesday, February 12, 2014 01:44 PM

Pharmaceutical and life sciences (PLS) merger and acquisition volume and value increased in the fourth quarter of 2013, finishing the year for deal activity on a high note,according to Pharmaceutical and Life Sciences Deals Insights Quarterly, a quarterly analysis of M&A trends and outlook for the PLS sector issued by PwC. PwC’s Health Industries Group is an advisor to public and private organizations across the health industries.

More... »

VC investment in biotech sector soars in second quarter

Friday, July 19, 2013 02:18 PM

Venture capitalists invested $6.7 billion in 913 deals in the second quarter of 2013, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Venture capital investments decline in dollars and deal volume in Q3 2012

Friday, October 19, 2012 03:26 PM

Venture capitalists invested $6.5 billion in 890 deals in the third quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

Venture capital investment in life sciences down 9%

Friday, July 20, 2012 02:45 PM

Despite venture capitalists investing $7 billion in 898 deals in the second quarter of 2012—a 17% climb in terms of dollars and an 11% rise in the number of deals compared to the first quarter of 2012, when $6 billion was invested in 809 deals—the life sciences sector (biotechnology and medical devices) saw a 9% drop in funding dollars and a 6% drop in deals from the prior quarter, to $1.4 billion going into 174 deals in Q2.

According to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters, the total number of early stage deals reached the highest quarterly total since Q1 2001, with $2.1 billion going into 410 deals. That’s an 18% increase in dollars and a 28% increase in deals from the prior quarter. Overall, the software industry took in the highest level of funding of all industries with $2.3 billion invested in Q2, the highest investment total for the sector since the Q2 2001.

More... »

Life Sciences venture capital investing falls in first quarter

Tuesday, April 24, 2012 12:21 PM

Venture capitalists invested $5.8 billion in 758 deals in the first quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. Quarterly venture capital (VC) investment activity fell 19% in terms of dollars and 15% in the number of deals compared to the fourth quarter of 2011, when $7.1 billion was invested in 889 deals.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs